In recent years, the development of wireless technologies has led to fast growth in mobile networks, especially with the rise of 5G New Radio (5G NR). A huge number of base stations (BSs) are mandatory to serve the growth of mobile services, which has led to concerns about the increase in electromagnetic field (EMF) radiation exposure levels. To control the overall power emitted by EMF transmitters, international bodies have set maximum exposure limits. This paper investigates the compliance distances (CDs) of shared sites by a group of Mobile Network Operators (MNO) as multi-operators operating with multi-technology and sharing the same tower. The study investigated the CDs of the most two commonly used types of sharing sites, macro and indoor-Based solution sites (IBS). In addition, the study analyzed the power densities and total exposure ratios for the general public and occupational workers in each sharing scenario. The results showed that, compared with a single MNO, the CD increased by 41% in the case of two MNOs, 73% for three MNOs, and 100% for four MNOs. The EMF site sharing scale-up formula was used to estimate the increase in CDs for N number of MNOs assuming that all MNOs use the same site configuration. In addition, the results showed that 5G has the highest contribution to the total exposure ratio (TER) at the CD in the main direction of the antennae.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919820 | PMC |
http://dx.doi.org/10.3390/s23031588 | DOI Listing |
BMC Health Serv Res
January 2025
Mayo Clinic Health System Northwest Wisconsin, Eau Claire, Wisconsin, USA.
Background: Interpreter service mode (in person, audio, or video) can impact patient experiences and engagement in the healthcare system, but clinics must balance quality with costs and volume to deliver services. Videoconferencing and telephone services provide lower cost options, effective where on site interpreters are scarce, or patients with limited English proficiency (LEP) and/or interpreters are unable to visit healthcare centers. The COVID 19 pandemic generated these conditions in Northwest Wisconsin (NWWI).
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Division of Diabetes & Nutritional Sciences, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK; Catholic University of the Sacred Heart, Rome, Italy; University Polyclinic Foundation Agostino Gemelli IRCCS, Rome, Italy.
Biol Rev Camb Philos Soc
January 2025
Wildlife Observatory of Australia (WildObs), Queensland Cyber Infrastructure Foundation (QCIF), Brisbane, Queensland, 4072, Australia.
Camera traps are widely used in wildlife research and monitoring, so it is imperative to understand their strengths, limitations, and potential for increasing impact. We investigated a decade of use of wildlife cameras (2012-2022) with a case study on Australian terrestrial vertebrates using a multifaceted approach. We (i) synthesised information from a literature review; (ii) conducted an online questionnaire of 132 professionals; (iii) hosted an in-person workshop of 28 leading experts representing academia, non-governmental organisations (NGOs), and government; and (iv) mapped camera trap usage based on all sources.
View Article and Find Full Text PDFJ Mol Evol
January 2025
Department of Plant and Soil Sciences, 311 Plant Science Building, University of Kentucky, Lexington, KY, 40546-0312, USA.
Amino acid racemases catalyze the interconversion of L- and D-amino acids, maintaining intracellular levels of both D- and L-amino acids. While alanine and glutamate racemases are widespread in bacteria, serine racemase (SerR) is predominantly found in animals. Recently, homologs of animal SerR were reported in some bacterial genomes, but their evolutionary distribution and functional roles remain poorly understood.
View Article and Find Full Text PDFDiabetologia
January 2025
Internal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.
Aims/hypothesis: COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications.
Methods: This 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!